Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01065194
Other study ID # 2008-007407-86
Secondary ID
Status Recruiting
Phase Phase 3
First received February 8, 2010
Last updated August 27, 2010
Start date August 2009
Est. completion date August 2011

Study information

Verified date August 2009
Source Medical University Innsbruck
Contact Johann Altenberger, MD
Phone +436624482
Email j.altenberger@salk.at
Is FDA regulated No
Health authority Austria: Agency for Health and Food SafetyGreece: National Organization of Medicines
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effects of a pulsed application of Levosimendan versus placebo on the composite end-point functional capacity and quality of life.


Description:

BACKGROUND Significant advances have been made in the treatment of congestive heart failure (CHF) in the past few years. Neurohumoral therapy with ACE-inhibitors, ß-blockers and aldosterone antagonists has been established to significantly reduce morbidity and mortality. However, despite the advances of modern therapy advanced CHF remains a syndrome with a poor prognosis. Additionally, this syndrome is associated with poor quality of life and leads to progressive debiliation and cardial cachexia. Repeat hospitalizations for acute heart failure are common among severe CHF patients. Besides the discomfort for the patients hospital admissions constitute the lion's share of the health expenditure for the heart failure syndrome.

Inotropic support is provided to patients suffering acute heart failure refractory to neurohumoral therapy. This approach is performed according to the AHA/ACC- as well as to ESC Guidelines for therapy of CHF. Inotropic therapy is targeted on hemodynamic stabilization, improvement of functional status, and reduction of rehospitalization.

Moreover, in many centres treatment with inotropes such as dobutamine and milrinone are an integral part of the applied bridge to transplant concept in severe heart failure patients. In fact, continuous or pulsed inotropic support in severe heart failure patients has been tested repeatedly in small clinical studies.

Intermittent ambulatory low dose administration of dobutamine versus conventional therapy did not improve functional capacity in the DICE-Trial. By contrast, several case series with different dose regimens of dobutamine indicated improvement of functional status.

TRIAL RATIONALE Based on its pharmacologic profile Levosimendan appears to be promising in the treatment of severe chronic heart failure functional NYHA class III/IV to improve quality of life and physical activity and to reduce hospital admissions for acute heart failure.

Repeat drug administration may be superior over a single shot therapy to maintain beneficial long-term results.

For economical reasons and for the sake of the patients comfort drug administration should ideally be managed on an outpatient basis rather than in the hospital. Therefore and for practical reasons, a time period of six hours for drug administration might be reasonable.

Dosing of the drug will be based on the experiences in the Russlan Trial and on a small case report by Martys. In the latter study serial administration of levosimendan for 6 hours (bolus of 12 mcg/kg followed by a continuous infusion of 0,1 μg/kg/min for 50min and 0,2 μg/kg/min for the next 5 hours) induced a significant fall of BNP.

In an outpatient setting, however, a bolus should be not be given for safety reasons.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date August 2011
Est. primary completion date August 2011
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Patients with chronic stable heart failure NYHA III and IV diagnosed at least 3 months before inclusion

- 6-min.-walk-test < 350 meters

- EF < 35 %

- Age > 20 years

- Optimized and individualised neurohormonal background therapy according to ESC-guidelines for the treatment of chronic heart failure.

- Patient has signed informed consent

Exclusion Criteria:

- Hospitalization for decompensated heart failure requiring i.v. diuretics within the last month before randomization

- History of torsades des pointes

- Allergy to Levosimendan or any of the excipients

- Administration of inotropes in the last 4 weeks

- Potassium <3,5 and >5,5 mmol/l

- Systolic blood pressure <= 100 mmHg

- Women at childbearing age without using effective contraceptives ( oral contraceptives, intrauterine contraceptive devices) unless surgical sterilisation has been undertaken.

- Female patients who are pregnant or nursing

- Creatinin Clearance < 30ml/min/m2

- Severe anemia (Hb < 10 mg /dl)

- Mechanical obstruction affecting the ventricular filling or the outflow or both

- Patients with non compliance

- Severe conditions, which make the patient unsuitable to participate in a study as judged by the investigator

- Severe liver disease

- Percutaneous coronary intervention within the last 1 months

- Coronary bypass surgery within the last 3 months

- Planned HTX within the next six months

- Patient involved in another clinical trial

- De-nove heart failure

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Levosimendan
Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 µg/kg/min without a bolus
Placebo
Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 µg/kg/min without a bolus.

Locations

Country Name City State
Austria Medical University Innsbruck Innsbruck
Austria Allg. öffentliches Krankenhaus der Elisabethinen Linz
Austria Allgemeine Krankenhaus der Stadt Linz Linz
Austria Krankenhaus der Barmherzigen Schwestern Linz
Austria Paracelsus Medical University Salzburg Salzburg
Austria Landesklinikum St. Poelten St. Poelten
Austria Kaiserin Elisabeth Spital Vienna Vienna
Austria Klinikum Wels Grieskirchen Wels
Greece G. Gennimatas General Hospital Athens
Greece Heart Failure Clinic, Attikon University Hospital Athens
Greece Hippokration General Hospital Athens

Sponsors (2)

Lead Sponsor Collaborator
Medical University Innsbruck Orion Corporation, Orion Pharma

Countries where clinical trial is conducted

Austria,  Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary proportion of patients showing an improvement in the six-minutes walk test and a higher scoring in the Kansas City Cardiomyopathy Questionnaire (KCCQ) 24 weeks No
Secondary effects of a pulsed application of levosimendan on event free survival 8 weeks from randomization No
Secondary effects of a pulsed application of levosimendan on event free survival 24 weeks from randomization No
See also
  Status Clinical Trial Phase
Terminated NCT03346278 - Text Message Intervention to Improve Cardiac Rehab Participation N/A
Completed NCT02696967 - A Study of CLR325 in Chronic Stable Heart Failure Patients. Phase 2
Recruiting NCT03834155 - Enhancing Cardiac Rehabilitation Through Behavioral Nudges N/A
Withdrawn NCT04507347 - Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus Phase 3
Completed NCT02204449 - Cardiac Rehabilitation Peer Mentorship N/A
Completed NCT00663195 - Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure Phase 4
Completed NCT00664222 - Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF) Phase 4
Completed NCT00663494 - Matrix Metalloproteinase (MMP) in Heart Failure N/A
Recruiting NCT05034549 - Noninvasive Ventilation for Chronic Heart Failure N/A